Asthma and COPD Therapies Forecast 2014 2024

www.visiongain.com

Contents

1. Report Overview

1.1 Global Asthma and COPD Therapies Market Overview

1.2 Global Asthma and COPD Therapies Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies

2.1 The Pharmaceutical Industry: a Very Brief Overview

2.2 Overview of Respiratory Diseases

2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive

2.3 What is Asthma?

2.3.1 Trends in Asthma Prevalence

2.3.2 Pathophysiology of Asthma

2.3.3 Symptoms of Asthma

2.3.4 Causes and Triggers for Asthma

2.3.5 Treatment of Asthma

2.3.6 Guidelines for Asthma Treatment

1. Report Overview

2. Introduction to Asthma and COPD Therapies

www.visiongain.com

Contents

2.3.7 Drug Treatments for Asthma

2.3.8 Drug Delivery Methods in Asthma

2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?

2.4.1 Trends in COPD Prevalence

2.4.2 Pathophysiology of COPD

2.4.3 Signs and Symptoms of COPD

2.4.4 Treatment of COPD

2.4.5 Drug Treatments for COPD

2.4.6 Guidelines for COPD Treatment

2.5 Major Drug Classes in the Treatment of Asthma and COPD

2.5.1 Bronchodilators

2.5.1.1 Beta2-Agonists

2.5.1.2 Anticholinergics

2.5.2 Anti-Inflammatory Drugs

2.5.2.1 Corticosteroids

2.5.2.2 Leukotriene Receptor Antagonists

2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease

2.5.3 Combination Drugs

2.5.4 Drugs for Allergic Rhinitis

2.6 Phases of Clinical Trials

2.7 Scope of this Report

2.8 Currency Exchange Rates in This Report

www.visiongain.com

Contents

3. Asthma and COPD Therapies: World Market 2014-2024

3.1 The World Respiratory Drugs Market by Therapeutic Area

3.2 The World Asthma and COPD Therapies Market in 2013

3.2.1 Leading Asthma and COPD Therapies

3.2.2 Leading Companies in the Asthma and COPD Therapies Market

3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-2024

3.3.1 World Asthma Therapies Market: Sales Forecast 2014-2024

3.3.2 World COPD Therapies Market: Sales Forecast 2014-2024

3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-2024

3.5 Combination Drugs Lead the Asthma and COPD Therapies Market

3.6 How Will Segmental Market Shares Change to 2024?

3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-2024

3.7 Asthma and COPD Therapies: Trends and Developments

3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers

3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Leading National Markets 2014-2024

4.1 Regional Breakdown of the World Asthma and COPD Therapies Market

4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-2024

4.2.1 How Will Regional Market Shares Change to 2024?

4.3 National Breakdown of the World Asthma and COPD Therapies Market

4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-2024

4.4.1 How Will National Market Shares Change to 2024?

3. Asthma and COPD Therapies: World Market 2014-2024

4. Leading National Markets 2014-2024

www.visiongain.com

Contents

4.5 The US Asthma and COPD Therapies Market 2014-2024

4.5.1 US Asthma and COPD Therapies Market Forecast 2014-2024

4.5.2 US Asthma and COPD Therapies Market: Trends and Developments

4.5.2.1 Increasing COPD Prevalence in the US

4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence

4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair

4.6 Japanese Asthma and COPD Therapies Market 2014-2024

4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-2024

4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments

4.6.2.1 Generic Penetration to Reach 60% by 2018?

4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform

4.7 EU5 Asthma and COPD Therapies Market 2014-2024

4.7.1 German Asthma and COPD Therapies Market Forecast 2014-2024

4.7.2 French Asthma and COPD Therapies Market Forecast 2014-2024

4.7.3 UK Asthma and COPD Therapies Market Forecast 2014-2024

4.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-2024

4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-2024

4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments

4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law

4.7.6.2 France: Social Security Finance Bill 2014

4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes

4.7.6.4 Italy: Austerity Measures Limiting Growth

4.7.6.5 Spain: The Start of Recovery in the Spanish Economy

4.8 BRIC Asthma and COPD Therapies Market 2014-2024

www.visiongain.com

Contents

4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-2024

4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments

4.8.2.1 China’s Industrial Future and Asthma/COPD

4.8.2.2 Expansion of Healthcare Coverage and Reimbursement

4.8.2.3 Price Controls and the Anhui Model

4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-2024

4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments

4.8.4.1 Increasing Access to Medicines

4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-2024

4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments

4.8.6.1 Drug Prices Control Order 2013

4.8.6.2 Expansion of Healthcare Provision

4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-2024

4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments

4.8.8.1 No Embargo on Foreign Drug Imports

4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry

4.9 Mexican Asthma and COPD Therapies Market 2014-2024

4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024

4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments

4.9.2.1 Seguro Popular: Mexican Healthcare Reform

4.9.2.2 COFEPRIS: Regulatory Changes and Improvements

4.9.2.3 Mexico’s Agreement for Innovation

www.visiongain.com

Contents

5. Bronchodilator Monotherapy Market 2014-2024

5.1 Introduction to Bronchodilator Monotherapy

5.2 The Bronchodilator Monotherapy Market in 2013

5.2.1 Leading Bronchodilators in 2013

5.3 Bronchodilator Monotherapy: Market Forecast 2014-2024

5.4 How Will Market Shares by Drug Class Change to 2024?

5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-2024

5.5.1 Leading SABAs in 2013

5.5.2 SABAs: Market Forecast 2014-2024

5.5.3 Market Share of Leading SABAs to 2024

5.5.4 Ventolin (salbutamol, GSK)

5.5.4.1 Ventolin: Sales Forecast 2014-2024

5.5.5 ProAir (salbutamol, Teva)

5.5.5.1 ProAir: Sales Forecast 2014-2024

5.5.6 Proventil (salbutamol, Merck)

5.5.6.1 Proventil: Sales Forecast 2014-2024

5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)

5.5.7.1 Xopenex: Sales Forecast 2014-2024

5.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-2024

5.6.1 Leading LABAs in 2013

5.6.2 LABAs: Market Forecast 2014-2024

5.6.3 Market Share of Leading LABAs to 2024

5.6.4 Foradil (formoterol, Merck/Novartis)

5.6.4.1 Foradil: Sales Forecast 2014-2024

5. Bronchodilator Monotherapy Market 2014-2024

www.visiongain.com

Contents

5.6.5 Serevent (salmeterol, GSK)

5.6.5.1 Serevent: Sales Forecast 2014-2024

5.6.6 Arcapta/Onbrez (indacaterol, Novartis)

5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-2024

5.6.7 Brovana (arfomoterol, Dainippon Sumitomo)

5.6.7.1 Brovana: Sales Forecast 2014-2024

5.6.8 Striverdi (olodaterol, Boehringer Ingelheim)

5.6.8.1 Striverdi: Sales Forecast 2014-2024

5.7 The Anticholinergics Market 2014-2024

5.7.1 Leading Anticholinergics in 2013

5.7.2 Anticholinergics: Market Forecast 2014-2024

5.7.3 Market Share of Leading Anticholinergics to 2024

5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)

5.7.4.1 Spiriva: Sales Forecast 2014-2024

5.7.5 Spiriva: Recent Developments

5.7.5.1 Safety Concerns and the UPLIFT Trial

5.7.5.2 Results of the POET Study

5.7.5.3 Competition from Combination Products

5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)

5.7.6.1 Atrovent: Sales Forecast 2014-2024

5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)

5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024

www.visiongain.com

Contents

6. Anti-Inflammatory Drugs Market 2014-2024

6.1 Introduction to Anti-Inflammatory Drugs

6.2 The Anti-Inflammatory Drugs Market in 2013

6.2.1 Leading Anti-Inflammatory Drugs in 2013

6.3 Anti-Inflammatory Drugs: Market Forecast 2014-2024

6.4 How Will Market Shares by Drug Class Change to 2024?

6.5 The Corticosteroids Market 2014-2024

6.5.1 Leading Corticosteroids in 2013

6.5.2 Corticosteroids: Market Forecast 2014-2024

6.5.3 Market Share of Leading Corticosteroids to 2024

6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)

6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024

6.5.5 Pulmicort (budesonide, AstraZeneca)

6.5.5.1 Pulmicort: Sales Forecast 2014-2024

6.5.6 QVAR (beclometasone, Teva)

6.5.6.1 QVAR: Sales Forecast 2014-2024

6.5.7 Asmanex (mometasone, Merck)

6.5.7.1 Asmanex: Sales Forecast 2014-2024

6.6 The Anti-Leukotrienes Market 2014-2024

6.6.1 Leading Anti-Leukotrienes in 2013

6.6.2 Anti-Leukotrienes: Market Forecast 2014-2024

6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2024

6.6.3 Singulair (montelukast, Merck)

6.6.3.1 Singulair: Sales Forecast 2014-2024

6. Anti-Inflammatory Drugs Market 2014-2024

www.visiongain.com

Contents

6.7 The Monoclonal Antibodies Market 2014-2024

6.7.1 Monoclonal Antibodies: Market Forecast 2014-2024

6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2024

6.7.2 Xolair (omalizumab, Novartis/Roche)

6.7.2.1 Xolair: Sales Forecast 2014-2024

6.7.3 Cinquil (reslizumab, Teva)

6.7.3.1 Cinquil: Sales Forecast 2014-2024

6.7.4 Mepolizumab (Bosatria, GSK)

6.7.4.1 Mepolizumab: Sales Forecast 2014-2024

6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)

6.7.5.1 Benralizumab: Sales Forecast 2014-2024

6.7.6 Lebrikizumab (RG3637, Roche)

6.7.6.1 Lebrikizumab: Sales Forecast 2014-2024

6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)

6.7.7.1 Dupilumab: Sales Forecast 2014-2024

7. Combination Drugs Market 2014-2024

7.1 Introduction to Combination Drugs

7.1.1 Leading Combination Drugs in 2013

7.2 Combination Drugs: Market Forecast 2014-2024

7.3 How Will Market Shares by Drug Change to 2024?

7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)

7.3.1.1 Advair/Seretide: Sales Forecast 2014-2024

7.3.2 Symbicort (budesonide/formoterol, AstraZeneca)

7. Combination Drugs Market 2014-2024

www.visiongain.com

Contents

7.3.2.1 Symbicort: Sales Forecast 2014-2024

7.3.2.2 Symbicort: The SMART Concept

7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)

7.3.3.1 Combivent: Sales Forecast 2014-2024

7.3.4 Dulera (formoterol/mometasone, Merck)

7.3.4.1 Dulera: Sales Forecast 2014-2024

7.4 Recently Launched Combination Drugs

8. Leading Companies in the Asthma and COPD Therapies Market

8.1 Asthma and COPD Therapies: Increasing Competition

8.1.1 Leading Companies in Asthma and COPD in 2013

8.1.2 Leading Companies: Market Forecast 2014-2024

8.1.3 How Will Leading Companies’ Market Shares Change to 2024?

8.2 AstraZeneca

8.2.1 AstraZeneca: Asthma and COPD Therapies

8.2.2 AstraZeneca: Sales Forecast 2014-2024

8.2.3 AstraZeneca: Products in Development

8.2.4 AstraZeneca: Recent Developments

8.2.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio

8.2.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug

Pipeline

8.2.4.3 AstraZeneca Rejects Pfizer Takeover Bid

8.3 Boehringer Ingelheim

8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies

8. Leading Companies in the Asthma and COPD Therapies Market

www.visiongain.com

Contents

8.3.2 Boehringer Ingelheim: Sales Forecast 2014-2024

8.3.3 Boehringer Ingelheim: Products in Development

8.3.4 Boehringer Ingelheim: Recent Developments

8.3.4.1 Expansion of Respimat Manufacturing Capacity

8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study

8.3.4.3 Ben Venue Laboratories Shut Down

8.4 GSK

8.4.1 GSK: Asthma and COPD Therapies

8.4.2 GSK: Sales Forecast 2014-2024

8.4.3 GSK: Products in Development

8.4.4 GSK: Recent Developments

8.4.4.1 Breo/Relvar and Anoro: Recently Launched Combination Drugs

8.4.4.2 Arnuity Ellipta Approved in the US

8.4.4.3 GSK Divests OTC Products

8.4.4.4 GSK Asset Swap with Novartis to Restructure Consumer Health

8.4.4.5 GSK Presents Data on Eosinophil Levels and COPD

8.5 Merck & Co. (Merck)

8.5.1 Merck: Asthma and COPD Therapies

8.5.2 Merck: Sales Forecast 2014-2024

8.5.3 Merck: Products in Development

8.5.4 Merck: Recent Developments

8.5.4.1 Bayer Acquires Merck’s Consumer Health Business

8.5.4.2 FDA Rejects Singulair OTC Switch

8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck

www.visiongain.com

Contents

8.6 Novartis

8.6.1 Novartis: Asthma and COPD Therapies

8.6.2 Novartis: Sales Forecast 2014-2024

8.6.3 Novartis: Products in Development

8.6.4 Novartis: Recent Developments

8.6.4.1 Novartis Restructures Following Strategic Review

8.6.4.2 Novartis Presents Data on Ultibro and Seebri

8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK

8.7 Roche

8.7.1 Roche: Asthma and COPD Therapies

8.7.2 Roche: Sales Forecast 2014-2024

8.7.3 Roche: Products in Development

8.8 Teva

8.8.1 Teva: Asthma and COPD Therapies

8.8.2 Teva: Sales Forecast 2014-2024

8.8.3 Teva: Products in Development

8.8.4 Teva: Recent Developments

8.8.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2014-2024

9.1 A Strong Asthma and COPD Pipeline

9.2 The Bronchodilators Pipeline

9.2.1 Bronchodilators: Phase 3 Pipeline

9.2.1.1 PX1439 and PX1442 (Prosonix)

9. Asthma and COPD Therapies Pipeline Analysis 2014-2024

www.visiongain.com

Contents

9.2.1.2 PT001 (glycopyrronium, AstraZeneca)

9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)

9.2.1.4 GW642444 (vilanterol, GSK)

9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)

9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)

9.2.1.7 QVAR BAI (beclometasone, Teva)

9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)

9.2.2 Bronchodilators: Phase 2 Pipeline

9.2.3 Bronchodilators: Phase 1 and Preclinical Pipeline

9.3 The Anti-Inflammatory Drugs Pipeline

9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline

9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)

9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)

9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)

9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)

9.3.1.5 Favolir (budesonide, Vectura)



9.3.4 Anti-Inflammatory Drugs: Preclinical Pipeline

9.4 The Combination Drugs Pipeline

9.4.1 Combination Drugs: Phase 3 Pipeline

9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)

9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)

9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)

www.visiongain.com

Contents

9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer

Ingelheim)

9.4.1.5 Easyhaler Combination Drugs (Orion)

9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)

9.4.2 Combination Drugs: Phase 2 Pipeline

9.4.3 Combination Drugs: Phase 1 and Preclinical Pipeline

9.5 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market

2014-2024

10.1 SWOT Analysis of the Asthma and COPD Therapies Market

10.2 Strengths

10.2.1 Increasing Prevalence and Disease Burden

10.2.2 High Costs of Treatment

10.2.3 The Changing Perception of COPD

10.2.4 Patient Education: Understanding the Severity of Respiratory Disease

10.2.5 Lifecycle Management Strategies to Counter Patent Expiry

10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion

10.2.7 Developments in Diagnostics

10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD

10.2.7.2 Biological Markers in COPD

10.3 Weaknesses

10.3.1 Under-Diagnosis: the ‘Ghost Population’

10.3.2 Side-Effects of Drug Classes

10. Qualitative Analysis of the Asthma and COPD Therapies Market

2014-2024

www.visiongain.com

Contents

10.3.3 Patent Cliff for Devices

10.3.4 Low Patient Adherence

10.4 Opportunities

10.4.1 Patient Phenotyping and Personalised Medicine

10.4.2 A Strong R&D Pipeline

10.4.2.1 Ultra-Long-Acting Beta2-Agonists

10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)

10.4.2.3 Monoclonal Antibodies

10.4.2.4 LAMA/LABA Combinations

10.4.3 Growth in Emerging Markets

10.4.4 Opportunities in Telehealth

10.5 Threats

10.5.1 Patent Expiry and Generic Competition

10.5.2 Pharmacy Benefit Managers and Cost Control

10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD

10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market

10.6.1 Rivalry Among Competitors [Medium]

10.6.2 Threat of New Entrants [Medium]

10.6.3 Power of Suppliers [Medium]

10.6.4 Power of Buyers [High]

10.6.5 Threat of Substitutes [Low]

www.visiongain.com

Contents

11. Research Interviews

11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler

Institute of Pulmonary Pharmacology, King’s College London

11.1.1 Treating Different Phenotypes of Asthma and COPD

11.1.2 Personalised Medicine and Improved Existing Drug Classes

11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment

11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD

11.1.5 Monoclonal Antibodies in Severe Asthma

11.1.6 Healthcare Costs and the Importance of Prevention

11.1.7 Areas to Improve Diagnosis and Treatment of Asthma

11.1.8 The Importance of Adherence and Early Diagnosis

11.1.9 Developments in Alpha-1 Antitrypsin Deficiency

11.1.10 Other Trends and Developments in Asthma and COPD

11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD

11.2.1 Asthma and COPD Treatments in 2014-2024

11.2.2 Personalised Therapies for Asthma and COPD?

11.2.3 Drivers and Restraints in the Market

11.2.4 The Outlook for the Asthma and COPD Market

11.3 Interview with Monica Fletcher, Chief Executive of Education for Health and Chair of the

European Lung Foundation (ELF), Sheffield, UK

11.3.1 The Importance of Education

11.3.2 Educating Healthcare Professionals and Patients

11.3.3 Missing the Diagnosis of COPD in Some Patient Populations

11.3.4 Global and Gender Issues in COPD

11. Research Interviews

www.visiongain.com

Contents

11.3.5 Improving Shared Understanding and Correct Inhaler Technique

11.3.6 The Growing Importance of Online Education

11.3.7 Engaging Patients Using Telehealth?

11.3.8 The Changing Impact of Education on Asthma and COPD

11.4 Interview with Daphne Tsitoura, Senior Medical Director, Clinical Drug

Development/Discovery Medicine, GlaxoSmithKline, UK

11.4.1 Unmet Needs in Asthma

11.4.2 The Asthma Market: Reaching Saturation?

11.4.3 Phenotypically-Tailored Therapies?

11.4.4 Difficulties with COPD Diagnosis

11.4.5 Importance of Inhalers in the Asthma and COPD Market

11.4.6 Research Emphasis on COPD?

11.4.7 Combinations for COPD

11.4.8 Views on Telehealth

11.4.9 Views on Personalised Medicine

11.4.10 On Novel Targets

11.4.11 The Ten-Year Outlook for the Asthma and COPD Market

11.5 Interview with Barbara Yawn, Director of Research at Olmsted Medical Center and Adjunct

Professor, Department of Family and Community Health, University of Minnesota, USA

11.5.1 Unmet Needs in Asthma

11.5.2 The Impact of Inhalers in Asthma and COPD

11.5.3 The Impact of New Drug Classes for COPD

11.5.4 Towards Personalised Medicine in Asthma and COPD

11.5.5 Views on Leukotriene Inhibitors

11.5.6 Anti-Inflammatory Drugs: More Research Required

www.visiongain.com

Contents

11.5.7 LABA Monotherapy Drugs: Fading Away?

11.5.8 LABA/LAMA Combination Drugs in COPD

11.5.9 Views On Telehealth

11.5.10 Under-Diagnosis in COPD

11.5.11 The Ten-Year Outlook for the Asthma and COPD Market

11.6 Interview with Ahmed Wagih, Product Manager, Respiratory Franchise (Seretide, Flixotide

and Ventolin) at GSK, UK

11.6.1 Rising Prevalence of COPD in the Middle East

11.6.2 Towards Personalised Medicine

11.6.3 Changes to Treatment Guidelines for Asthma and COPD

11.6.4 Key Areas of Focus in Asthma and COPD

11.6.5 Views on Generic Competition

11.6.6 Improving COPD Diagnostics

11.6.7 Views on LAMA/LABA Combinations

11.6.8 Views on Telehealth

12. Conclusions

12.1 Asthma and COPD Therapies: A Maturing Market

12.2 The World Asthma and COPD Therapies Market in 2013

12.2.1 Current Leading Asthma and COPD Therapies Segments

12.2.2 Leading Asthma and COPD Therapies

12.2.3 Leading Asthma and COPD Therapies Companies

12.2.4 Leading Regional and National Markets

12.3 World Asthma and COPD Therapies Market Forecast 2014-2024

12. Conclusions

www.visiongain.com

Contents

12.4 Asthma and COPD Therapies Late-Stage Pipeline

12.5 The Future of the Asthma and COPD Therapies Market?

12.5.1 Growth in Anti-Inflammatory and Combination Drugs

12.5.2 Towards Personalised Medicine

12.5.3 Unmet Needs in Asthma and COPD

12.5.4 Strategies for Growth in 2014-2024

www.visiongain.com Page 122

Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies

4.9 Mexican Asthma and COPD Therapies Market 2014-2024

Factors underlying the prevalence of asthma and COPD in Mexico include air pollution,

industrialisation and urbanisation, and a growing population. Air pollution is a widespread and

worsening problem in urban areas. The prevalence of asthma is higher in Mexico’s coastal states,

which may be due to the higher humidity causing dust to be suspended in the air and enter the

lungs more easily, or to the use of air conditioning systems that trap dust and moulds. There is also

a high rate of smoking, particularly in young people.

4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024

Visiongain estimates that in 2013, the Mexican asthma and COPD therapies market reached

$309m, representing 0.9% of the world market. In 2014 the Mexican market will increase to

$320m, up 3.5% on 2013. Like Brazil, the Mexican market is characterised by improving healthcare

provision and higher cost-sensitivity. Generic drugs for asthma and COPD are expected to gain

market share in the Mexican market. In August 2014 Mexico was the first Latin American market to

approve Novartis/Vectura’s generic version of Advair. The drug will be marketed as IrFlosol

ForSpiro in Mexico. Improvements to the Mexican drug approval process will also drive the market,

visiongain believes. Visiongain predicts that the Mexican market will grow with a CAGR of 4.5%

over 2013-2018 to reach $385m in 2018. The Mexican market will grow at a CAGR of 5.3% over

2018-2024 to reach $525m in 2024, representing an overall CAGR of 4.9% over 2013-2024.

Table 4.20 and Figure 4.23 show visiongain’s forecast for the Mexican asthma and COPD

therapies market from 2013 to 2024.

Table 4.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Mexico ($m) 309 320 333 347 363 385 402 423 454 486 507 525Annual Growth Rate (%) 3.5 4.0 4.3 4.4 6.2 4.5 5.0 7.5 7.0 4.2 3.6CAGR (%, 2013-2018 and 2018-2024)

4.5 5.3

CAGR (%, 2013-2024) 4.9 Source: visiongain 2014



As discussed in Chapter 8, GSK is developing fluticasone furoate as a phase 3 pipeline compound

for asthma.

6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024

Table 6.8 and Figure 6.12 show visiongain’s estimates of Flixotide/Flovent revenues over 2013-

2024.

Table 6.8 GSK: Flixotide/Flovent Revenue ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Flixotide/Flovent ($m) 1,245 1,283 1,321 1,349 1,376 1,307 1,242 1,192 1,144 1,110 1,088 1,077 Annual Growth Rate (%) 3.0 3.0 2.1 2.0 -5.0 -5.0 -4.0 -4.0 -3.0 -2.0 -1.0CAGR (%, 2013-2018 and 2018-2024)

1.0 -3.2

CAGR (%, 2013-2024) -1.3

Figure 6.12 GSK: Flixotide/Flovent Revenue ($m), AGR (%), 2013-2024

Flixotide/Flovent has been maintaining revenues at around $1,250m in USD terms in recent years,

and has had little direct mention in GSK’s financial reports. GSK reported Flixotide/Flovent

revenues of $1,245m in 2013. Visiongain estimates that sales for 2014 will reach $1,283m, up

3.0% on 2013. We predict that Flixotide/Flovent revenues will grow with a CAGR of 1.0% over

2013-2018 to reach $1,307m in 2018. The wide-ranging use of this drug across disease severity,

-6.0-5.0-4.0-3.0-2.0-1.00.01.02.03.04.0

0

200

400

600

800

1,000

1,200

1,400

1,600

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s ($

m)

Year Sales ($m) AGR (%)

Source: visiongain 2014

Source: visiongain 2014



8.5 Merck & Co. (Merck)

Merck & Co., Inc. (Merck) is a leading US pharmaceutical and healthcare company. Its business

activities are organised by product segment into Pharmaceuticals, Animal Health, Consumer Care

and Alliances. Its position in the asthma and COPD market has declined significantly in 2014 due

to patent expiry of Singulair. Table 8.15 provides an overview of Merck.

Table 8.15 Merck: Overview, 2014

Ranking in 2013 4Company Merck & Co., Inc. (Merck)

Notable Subsidiaries Schering-Plough (2009), Inspire Pharmaceuticals (2011)

Business Areas Pharmaceuticals, consumer health, vaccines, animal health

Established 1917 (initially in 1891, the US subsidiary of Merck KGaA)

Headquarters Whitehouse Station, New Jersey, US

Leading Drugs Singulair, Proventil, Asmanex, Dulera, Foradil

FY 2013 Revenue ($m) 44,033

FY 2013 Asthma & COPD Drugs Revenue ($m) 1,976

8.5.1 Merck: Asthma and COPD Therapies

The revenues and revenue shares of Merck’s leading drugs in 2013 are shown in Table 8.16 and

Figures 8.16 and 8.17.

Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013

Drug Revenue ($m) 2013 Revenue Share (%) 2013Singulair 1,196 60.5Dulera 324 16.4Asmanex 184 9.3Proventil 174 8.8Foradil (Merck) 98 5.0Total 1,976 100.0

Source: Merck & Co. 2014; visiongain 2014

Source: Merck 2014; visiongain 2014